Alzheimer's disease (AD) is a devastating neurological condition characterized by a progressive decline in cognitive performance accompanied by behavioral and psychological syndromes, such as depression and psychosis. The neurochemical correlates of these clinical manifestations now appear to involve dysfunctions of multiple neurotransmitter pathways. Because of the extensive serotonergic denervation that has been observed in the AD brain and the important role played by serotonin (5-HT) in both cognition and behavioral control, this neurotransmitter system has become a focus of concerted research efforts to identify new treatments for AD. 5-HT exerts its diverse physiological and pharmacological effects through actions on multiple receptor subtypes. One of the newest members of this family is the 5-HT 6 receptor, a subtype localized almost exclusively in the CNS, predominating in brain regions associated with cognition and behavior. With the subsequent development of selective 5-HT 6 receptor antagonists, preclinical studies in rodents and primates have elucidated the function of this receptor subtype in more detail. It is increasingly clear that blockade of 5-HT 6 receptors leads to an improvement of cognitive performance in a wide variety of learning and memory paradigms and also results in anxiolytic and antidepressant-like activity. These actions are largely underpinned by enhancements of cholinergic, glutamatergic, noradrenergic, and dopaminergic neurotransmission, together with learning-associated neuronal remodeling. A preliminary report that the cognitive enhancing properties of a 5-HT 6 receptor antagonist (namely, SB-742457) extends into AD sufferers further highlights the therapeutic promise of this mechanistic approach.
INTRODUCTION
Alzheimer's disease (AD) is the most common neurodegenerative disorder and poses the biggest unmet medical need in neurology, with more than 26 million sufferers today worldwide-a statistic expected to quadruple by the year 2050 as an unfortunate by-product of increasing life expectancy. 1 Clinically, AD is characterized by progressive cognitive decline associated with impairment in activities of daily living and behavioral symptoms such as depression, agitation, psychosis, and aggression that can vary in severity according to the stage of the disease.
The causes of AD are still rather poorly understood, and it is now considered probable that AD is of heterogenous origin, with various etiologies leading to the hallmark plaque and tangle pathology and profound neuronal loss. At the neurochemical level, some 20 to 30 years ago AD was thought to be primarily a disorder of cortical cholinergic innervation-the so-called cholinergic hypothesis of aging and AD. 2 Given the complexity and diversity of the cognitive and behavioral abnormalities observed in AD, however, it is highly likely that dysfunction of multiple neurotransmitter systems is at play. The observation that cholinesterase inhibitors, agents designed specifically to boost residual cholinergic transmission, are at best only partially effective in treating the clinical manifestations of AD, certainly supports this view. 3 More recently, deficits in the serotonergic, GABAergic, noradrenergic, dopaminergic, and glutamatergic pathways have all been described to track, to a greater or lesser extent, with cognitive and/or behavioral changes in AD (see Ramirez et al. 4 for a brief overview). From a therapeutic perspective, the serotonergic system appears to be a particularly attractive target, because it has been implicated not only in cognitive processes but also in depression, psychosis, and aggression. 4 Within this particular neurotransmitter pathway, the 5-HT 6 receptor class of serotonin receptors has received the most attention and interest in recent years, in line with the development of potent and selective tool molecules with which to probe its function. This review highlights the now compelling evidence-base showing that selective blockade of 5-HT 6 receptors results in a preclinical profile consistent with the potential to attenuate both the cognitive and the behavioral abnormalities of AD via modulation of multiple neurotransmitters and also synaptic plasticity. A first report that a 5-HT 6 receptor antagonist, SB-742457, 5 is of clinical benefit in AD patients (see http://www.gsk.com/investors/presentations/ 2007/neurosciences-seminar-dec07/jackie-hunter.pdf) provides further evidence of the therapeutic potential of this approach.
5-HT 6 RECEPTOR DISCOVERY, DISTRIBUTION AND GENETICS
The 5-HT 6 receptor is one of the most recent additions to the serotonin receptor family having been discovered by independent groups using molecular cloning approaches as recently as 1993. 6, 7 It is a 7 transmembrane receptor positively coupled to the Gs protein and thus activates cAMP. 6, 7 Several techniques have been used to assess the distribution of the 5-HT 6 receptor, which has proven to be almost exclusively localized within the CNS, being particularly abundant in regions that play key roles in modulating cognitive processes and neurotransmitter release. Using the highly selective 5-HT 6 receptor antagonist radioligand [
125 I]SB-258585, autoradiographic binding studies in the rat brain have demonstrated a high level of specific binding within striatum, nucleus accumbens, islands of Calleja, and olfactory tubercule. 8 More moderate levels of specific binding were shown within several regions of the hippocampal formation and layers of the cerebral cortex. These results are in general accord with mRNA and immunolabeling localization studies. 9, 10 The lack of receptors in the periphery corresponds to an absence of unwanted peripheral side effects for 5-HT 6 receptor antagonists, as observed to date in both preclinical and clinical studies.
The pattern of expression of 5-HT 6 receptors is remarkably similar between human and rat, 11 as is the potency of 5-HT 6 receptor antagonists (Table 1) , suggesting the potential value of this particular rodent species for translational studies. This is in contrast to the case for mouse, where brain levels of 5-HT 6 receptors are much lower than those found in human or rat, and where the affinity of 5-HT 6 receptor antagonists is also reduced compared with other species. 12 This is somewhat unfortunate, given that many experimental models designed to mimic various aspects of AD pathology have been developed using transgenic mice.
During their work on cloning the human 5-HT 6 receptor gene, Kohen et al. 13 identified a silent polymorphism at base pair 267 (C267T). Although this polymorphism does not produce any consequential change in the amino acid sequence of the protein, its discovery led to an explosion in genetic association studies investigating potential correlation with several CNS disorders. In brief, although there is evidence linking this polymorphism in several syndromes that affect cognition, including dementia and schizophrenia, these findings have not always been replicated in additional cohorts or ethnic groups, and their significance remains to be established (see Woolley et al. 11 and Mitchell and Neumaier 14 ).
DEVELOPMENT OF SELECTIVE TOOLS TO PROBE 5-HT 6 RECEPTOR FUNCTION
Once the 5-HT 6 receptor was discovered, a battery of compounds were soon assessed for affinity at this new subtype. Several molecules that were already in widespread clinical use as either antipsychotic (e.g., clozapine 15 ) or antidepressant (e.g., amitryptiline 6 ) agents were found to have high affinity for 5-HT 6 receptors, but none proved to be selective. Initial studies to explore the functional role of the 5-HT 6 receptor subtype in vivo relied on the use of antisense oligonucleotides that had to be administered directly into the brain. In a relatively short time, a number of potent and selective small molecular weight 5-HT 6 receptor antagonists became available, the first examples of which were Ro 04-6790 and Ro 63-0563, 16 quickly followed by the structurally distinct molecule SB-271046. 17, 18 Although all three compounds have proven to be extremely useful investigative tools, they are less than ideal for in vivo studies, mainly due to their poor ability to penetrate into the CNS after systemic dosing. Sustained discovery efforts have managed to synthesize orally active molecules with significantly enhanced brain penetrance characteristics while maintaining the excellent potency and selectivity of the earlier 5-HT 6 antagonist molecules. Examples in this category include SB-399885, 19 Ro 4368554, 20 and one of the most recently described compounds, SB-742457 (Table 1) . 5 This last molecule is of particular interest as the first example within this mechanistic class reported to show efficacy in AD patients.
In terms of defining the current understanding of the potential utility of 5-HT 6 receptor antagonists in AD, much of the pivotal data has been derived from a small subset of the available compounds. The key pharmacological and pharmacokinetic properties of these leading tool molecules are summarized in Table 1 , and the data from the now extensive behavioral profiling, mechanistic studies and recent clinical trials are described in detail in the next sections. The information available on other 5-HT 6 receptor antagonists, including those still believed to be in clinical development for cognitive disorders (Table 2) , is more limited, but is remarkably confirmatory (see Schreiber et al. 21 ). In contrast to the success in generating selective 5-HT 6 receptor antagonists, selective agonists have proven to be much more elusive and to date have had less of an impact on defining the role of 5-HT 6 receptors, especially in vivo. The most notable exceptions are WAY-466 and WAY-181187, two compounds that have recently been used in both cognitive and neurochemical studies.
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COGNITIVE ENHANCING AND BEHAVIORAL PROFILES OF 5-HT 6 RECEPTOR ANTAGONISTS
The first studies investigating the potential role of 5-HT 6 receptors in vivo were conducted using intracerebroventricularly administered antisense oligonucleotides in rats to induce receptor knockdown. 25 The reduced cortical 5-HT 6 receptor level was correlated with increased yawning and stretching behavior, which was almost completely abrogated by atropine, a nonselective antagonist of muscarinic receptors. This observation was confirmed and extended by a follow-up study in which the enhanced stretching behavior induced by the 5-HT 6 receptor antagonist Ro 04-6790 was blocked by the muscarinic antagonists atropine and scopolamine. 26 These findings indicate that the endogenous 5-HT 6 receptors are under tonic activation to suppress cholinergic neurotransmission. Because acetylcholine (ACh) was known to be directly involved in a range of cognitive and behavioral functions, including memory, anxiety, arousal, attention, and fatigue, 27 ,28 a potential therapeutic role for 5-HT 6 receptor antagonists in cognitive and psychiatric diseases became apparent.
This view gained further momentum when the 5-HT 6 receptor antisense oligonucleotides were demonstrated to improve spatial learning and memory in the Morris water maze test in normal rats. 29, 30 Additional work with Ro-04-6790 (10 and 30 mg/kg, i.p.) confirmed the influence of 5-HT 6 receptor blockade on cognitive processes relevant to the retention of information, but not on learning acquisition, in this paradigm. 30 SB-271046 (10 mg/kg, p.o.), was also shown to enhance retention but not acquisition in young unimpaired rats, using the Morris water maze, 31 suggesting that chronic administration may improve long-term retention of the task rather than directly modulate the learning process per se. However, a number of independent groups have attempted to replicate these findings with both Ro-04-6790 and SB-271046 in the Morris water maze without success. 32, 33 Different experimental protocols may contribute to these discrepancies, and further work is required to improve the validity and reliability of these results.
Alternative cognitive paradigms have been used to expand on previous reports documenting procognitive effects, using a wide range of 5-HT 6 receptor antagonists and a variety of tests and conditions that probe a number of cognitive domains (i.e., encoding, consolidation and storage, and retrieval). One such model, the object recognition test, has been used by a number of groups to ascertain 5-HT 6 receptor antagonist effects across a range of experimental manipulations (i.e., using delay or pharmacologically induced deficits in normal rats and naturally occurring deficits in aged rats) to provide confirmation of cognitive enhancement. This test is thought to engage the perirhinal and postrhinal cortex, where object processing is considered to be mediated and which has reciprocal connections with the hippocampus to provide an integration of event-related memories. 34 Both Ro-04-6790 (10 mg/kg, i.p.) and SB-271046 (10 mg/kg, i.p.) increased novel object recognition in normal adult rats after acute and chronic (lead-in) administration protocols, 35 in which the trial interval between the sam-ple and discrimination test was 4 h (the resulting differential between novel and familiar object exploration is typically abolished). Effects on consolidation and storage, rather than encoding or retrieval per se, were inferred from experiments in which both compounds were administered before, or immediately after, the sample trial. Pretreatment with the NMDA receptor antagonist MK-801 prevented the cognitive enhancing effect of Ro-04-6790 on delay-induced deficits in object recognition, suggesting that 5-HT 6 antagonists may enhance consolidation and storage processes through increasing central glutamatergic neurotransmission. 35 Another study examined the effects of a longer intertrial interval (e.g., 48 h) between the sample and discrimination phases, and showed significant dose-dependent improvements in novel object recognition with SB-271046 (0.3-10 mg/kg, i.p.). 36 Furthermore, SB-271046 (0.3-3.0 mg/kg, i.p.) has also been shown to dose-dependently reverse a 5-h novel object recognition memory deficit in aged F344 rats, 36 suggesting that 5-HT 6 receptor blockade confers cognitive benefit within an aged background. Procognitive effects with SB-399885 (10 mg/kg, p.o., unpublished observation) and Ro-4368554 (3 and 10 mg/kg, i.p.) 21 have been demonstrated in the object recognition paradigm, using adult rats, suggesting that this test is very sensitive to the cognitive enhancing effects of 5-HT 6 receptor blockade. Furthermore, when the nonselective muscarinic antagonist scopolamine was used to disrupt cognitive performance on the object recognition test in rats, by reducing central cholinergic neurotransmission, robust improvements were also generally reported for 5-HT 6 antagonists. Thus, the reversal of a scopolamine-induced object recognition deficit has been shown for Ro-04-6790 (10 mg/kg, i.p.), 37 SB-399885 (10 mg/kg, p.o.), 19 Ro-4368554 (3 and 10 mg/kg, i.p.) 21 ,38 Information on the general design and purpose of clinical trials was obtained from the U.S. National Institutes of Health http://www. clinicaltrials.govwebsite. Results data were obtained from press releases on the website of the sponsoring company. AD ϭ Alzheimer's disease; PD ϭ pharmacodynamic; PK ϭ pharmacokinetic.
and SB-742457 (1.5 mg/kg, p.o.), 5 and has formed a benchmark cognitive test for more recently discovered 5-HT 6 receptor antagonist compounds (e.g., SUVN-507). 39 Other tests sensitive to the behavioral and cognitive impairments induced by scopolamine (e.g., passive avoidance, autoshaping, social recognition, contextual fear-conditioning, Morris water maze) have also confirmed a procognitive profile with the majority of the aforementioned 5-HT 6 receptor antagonists, depending on the test conditions used and doses selected (see review by Mitchell and Neumaier 14 ). In studies modeling an age-induced impairment on cognitive performance in rats using the Morris water maze, a number of 5-HT 6 receptor antagonists have demonstrated significant reversal. SB-271046 (10 -20 mg/kg, p.o., and 1-6 mg/kg, i.p.), 36, 40 SB-399885 (10 mg/kg, p.o.), 19 and SB-742457 (1.5 mg/kg, p.o.) 5 have all shown consistent improvements in both acquisition and retention, suggesting that in aged rats this test is sensitive to the cognitive enhancing properties of several 5-HT 6 receptor antagonists. However, Ro-4368554 (1-10 mg/kg, p.o.) did not improve the performance of aged rats in the Morris water maze. 41 Notably, a potential additive or synergistic effect of SB-271046 (1.0 mg/kg, i.p.) with donepezil (0.3 mg/kg, i.p.) has been demonstrated using this paradigm, 36 suggesting that there maybe some utility in combining 5-HT 6 receptor antagonists with cholinesterase inhibitors to improve cognitive performance or to increase therapeutic responsiveness in AD.
More recently, the 5-HT 6 receptor agonist WAY-181187 has been shown to impair social recognition in rats, a profile commonly provoked by scopolamine. 24 When suboptimal doses of WAY-181187 and scopolamine were combined in this social memory paradigm, there was a synergistic shift toward a deficit, suggesting that tonic activation of the 5-HT 6 receptor can disrupt cognitive processes linked to reductions in cholinergic tone. Furthermore, SB-271046 (20 mg/kg, i.p.) abolished both the WAY-181187-induced and the scopolamineinduced social recognition deficit, further reinforcing the notion that 5-HT 6 receptor blockade improves cognitive function by modulating central cholinergic tone. The site of action for these studies was confirmed as being within the frontal cortex (using bilateral direct injections of WAY-181187 and SB-271046), 24 a key area involved with modulating cognitive function in this social recognition paradigm and one in which 5-HT 6 receptor localization has been reported. SB-399885 (1-30 mg/kg, p.o.) has also been shown to improve performance in an autoshaping and an attentional set shifting task in rats, which suggests a role for 5-HT 6 receptor blockade in enhancing cognitive flexibility. 42, 43 These findings may provide some basis for the potential treatment of social cognition and attentional deficits demonstrated in AD, schizophrenia, and other CNS disorders. A number of 5-HT 6 receptor antagonists are in development for cognitive disorders associated with schizophrenia (e.g., SGS-518) ( Table 2) .
In terms of translating the cognitive enhancing properties of 5-HT 6 antagonists from rodents to nonhuman primates, a limited number of studies have been conducted to assess this mechanism in monkeys. For example, SB-271046 (10 and 30 mg/kg, p.o.) was shown to improve correct responses in a delayed matching-to-sample test in a small number of aged rhesus monkeys with established delay-dependent impairments (unpublished data). Furthermore, SB-271046 (3 and 10 mg/kg, p.o.) was shown to significantly reverse MK-801-induced impairments on both perceptual visual discrimination and visuospatial conditional discrimination tasks (FIG. 1) , suggesting a modulatory effect on central glutamatergic pathways within the cortex and hippocampus. These results indicate that 5-HT 6 receptor blockade can enhance cognitive function in a primate species, and emerging data show that this observation also extends to humans.
A number of 5-HT 6 receptor antagonists, including several compounds still in development, have successfully undergone phase I clinical studies in healthy volunteers. In all cases, excellent safety and tolerability profiles have been observed after single or repeated doses, indicating no apparent liabilities for the 5-HT 6 receptor antagonist approach at this stage (Table 2) . For the most advanced compound, SB-742457, two phase II trials have recently been completed in subjects with mild-to-moderate AD. The first was reportedly a doseranging trial comparing SB-742457 with placebo, and the second was an exploratory study with SB-742457 and donepezil arms. Overall, these studies have demonstrated that SB-742457 is well tolerated in AD patients, with a safety profile comparable to placebo. Regarding therapeutic efficacy, SB-742457 produced an improvement in both cognitive and global function in AD as assessed by ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) and CIBICϩ (Clinician's Interview-Based Impression of Change-plus Caregiver Input), respectively. The effect size measured at the dose of 35 mg SB-742457 was similar to that of donepezil (see http://www.gsk.com/investors/presentations/2007/ neurosciences-seminar-dec07/jackie-hunter.pdf). These preliminary data represent the first demonstration of symptomatic benefit in AD for a 5-HT 6 receptor antagonist.
Regarding other behavioral symptoms associated with AD, such as anxiety and depression, there is evidence to suggest that 5-HT 6 receptor antagonists have both anxiolytic and antidepressant properties in preclinical models. For example, SB-399885 has been shown to be active in the Vogel conflict (1-3 mg/kg, i.p.) and the elevated-plus maze (0.3-3 mg/kg, i.p.) models of anxiety and in the forced swim test (10 mg/kg, i.p.) model of depression in rats. 44 The magnitudes of effects demonstrated were similar to those of reference standards (i.e., diazepam and imipramine for anxiety and depression, respectively). In addition, the same research group demonstrated an antidepressant profile in the rat forced swim test after the combined administration of subactive doses of SB-399855 (3 mg/kg, i.p.) with either desipramine (norepinephrine [NE] reuptake inhibitor) or bupropion (dopamine [DA] reuptake inhibitor), but not citalopram (5-HT reuptake inhibitor). 45 This evidence suggests that 5-HT 6 blockade may enhance central noradrenergic and dopaminergic tone within pathways relevant to antidepressant activity. A more recent study has confirmed that intrahippocampal administration of a 5-HT 6 antagonist (SB-258585) produces an anxiolytic and antidepressant profile in both Vogel conflict and forced swim tests, respectively, and suggests that the hippocampus, where 5-HT 6 receptors are indeed present, plays a key role in mediating these behaviors. 46 Such evidence suggests that 5-HT 6 receptor antagonists may improve both the cognitive and behavioral symptoms associated with AD by modulating multiple central neurotransmitter systems.
A number of studies have also pointed toward potential food intake and body weight reductions with 5-HT 6 receptor antagonists, suggesting potential therapeutic application in obesity. For example, early studies demonstrated effects of 5-HT 6 receptor-directed antisense oligonucleotides injected intracerebroventricularly on reducing food consumption and body weight gain. 30 Reductions in body weight gain were also reported for Ro-04-6790 (30 mg/ kg, i.p.). 30 Subsequent reports confirmed effects on food intake and body weight with the following 5-HT 6 antagonists: SB-271046, 11 SUVN-503 and SUVN-504, 47 E-6837, 48 and BVT compounds. 49 As a result of these preclinical rodent studies, several lead compounds are currently in development for obesity (i.e., SUVN-504, E-6837, PRX-07034, and BVT-74316). SB-742457, however, did not induce any significant body weight or food intake reductions at cognitive enhancing doses in preclinical species tested to date (unpublished data).
Overall, largely consistent effects have been demonstrated with 5-HT 6 receptor antagonists in preclinical models of cognition, indicative of enhancement of learning and memory related to the consolidation and storage of information. These properties appear to be underpinned, at least in part, by modulation of cholinergic and glutamatergic tone within reciprocal pathways between the cortex and hippocampus. This putative mechanism,
FIG. 1.
Reversal of MK-801-induced deficits in perceptual visual discrimination and visuospatial conditional discrimination tasks by SB-271046 in the common marmoset. MK-801 (0.015 mg/kg intramuscularly) produced a significant impairment in performance of both the perceptual visual discrimination (cortical-dependent) and visuospatial (hippocampal-dependent) tests, relative to saline-control administration (*). SB-271046 (3 and 10 mg/kg, p.o.; data shown for highest dose only) completely reversed ( †) these deficits back to a saline-control level of performance. The learning score refers to the number of trials required before the 90% correct criterion was met (i.e., 27 correct responses over 30 consecutive trials). The higher the learning score, the more trials needed to learn the task and thus the more difficult the marmoset found the task. The methodology used in this study was comparable to that reported previously. 95, 96 NS, nonsignificant compared with saline-controls. Data courtesy of Josie Harder, Bradford University.
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together with effects on noradrenergic and dopaminergic pathways, may also be relevant in the treatment of behavioral symptoms associated with AD, such as anxiety and depression. This therapeutic promise now appears to have translated to AD patients, based on the outcome of the first reported clinical trials with a 5-HT 6 receptor antagonist in this population. Recent rodent data suggest that there may be some synergistic or additive cognitive benefit in combining a 5-HT 6 receptor antagonist with a cholinesterase inhibitor, highlighting promise of a new paradigm for symptomatic treatment approaches for AD.
5-HT 6 RECEPTOR ANTAGONISTS MODULATE MULTIPLE NEUROTRANSMITTER PATHWAYS
Several microdialysis studies with selective 5-HT 6 receptor antagonists have provided direct evidence for the ability of 5-HT 6 receptor blockade to elevate cholinergic neurotransmission in different brain regions of freely moving adult rats, including the prefrontal cortex (4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl) phenylamine 50 and SB-399885 19 ) and the dorsal hippocampus (SB-271046 51 ). This neurochemical effect is corroborated by the ability of 5-HT 6 receptor antagonists to reverse learning and memory deficits induced by cholinergic antagonists.
Nonetheless, the procognitive properties of 5-HT 6 receptor antagonists are unlikely to be attributable solely to their effect on the cholinergic system. In addition to stimulating cholinergic neurotransmission, SB-271046 also induces the release of the excitatory neurotransmitter glutamate in the dorsal hippocampus and frontal cortex, as well as aspartate in the frontal cortex. 52, 53 Excitatory neurotransmission plays an important role in long-term potentiation, learning, and memory, as exemplified by the observed impairment of cognitive functions by blocking glutamate neurotransmission in a range of behavioral paradigms and by the loss of glutamatergic neurons in postmortem brain of AD sufferers. 54, 55 The glutamate-enhancing effect of 5-HT 6 receptor antagonism may therefore provide an additional mechanism for improving cognition. From a therapeutic point of view, it is of note that the induction of glutamate and ACh are independent processes, 53 so conceptually the demise of cholinergic neurons should not compromise the cognitive enhancing properties of 5-HT 6 receptor antagonists as mediated via elevation of glutamate release. 5-HT 6 receptor antagonists additionally stimulate the release of DA and NE in the prelimbic-infralimbic subregion of the medial prefrontal cortex. 56 This brain region is abundantly innervated by catecholaminergic neurons, and is associated with cognitive function, temporal organization of behavior, and behavioral flexibility. 57, 58 Although the expression profile of 5-HT 6 receptors in the brain has been extensively studied, the cellular localization and the neuronal circuitries that determine the neurochemical effects of these receptors are less well explored. Lesioning studies with the serotonergic neurotoxin 5,7-dihydroxytryptamine have shown that 5-HT 6 receptors are located postsynaptically to serotonergic neurons and do not serve a role as a serotonergic autoreceptor. 9 This is in line with the lack of effect of 5-HT 6 receptor antagonism on the extracellular levels of 5-HT in several brain regions. 53, 56 On the other hand, although 5-HT 6 receptor antagonists elevate the release of ACh, glutamate, NE, and DA, there has so far been no evidence for the expression of 5-HT 6 receptors on any of these neurons based on immunohistochemical, microdialysis, and neurochemical lesioning studies. 8, 11, 52, 53, 59, 60 Thus, the induction of these neurotransmitters is expected to be indirect.
Significantly, several reports now provide converging evidence that 5-HT 6 receptors are expressed on GABAergic neurons. First, immunohistochemical data show the presence of the receptors on medium spiny neurons in the striatum, 61 consistent with localization to GABA neurons. This is supported by the co-staining of 5-HT 6 receptors and the GABAergic neuronal marker glutamic acid decarboxylase 67 (GAD67) in several brain regions of the rat, including the hippocampus, cortex, basal ganglia, thalamus, and cerebellum. 11 Second, functional confirmation is provided by microdialysis studies on freely moving rats, showing increases in extracellular levels of GABA in the frontal cortex and dorsal hippocampus upon the administration of the 5-HT 6 receptor agonist WAY-466, as well as a reduction in the induced release of glutamate from an in vitro hippocampal culture. 22 In summary, cumulative data support a model of neural circuitry in which tonic activation of 5-HT 6 receptors expressed on GABAergic neurons leads to the induction of GABA release and in turn the inhibition of downstream cholinergic and glutamatergic neurons. Blockade of 5-HT 6 receptors effectively removes this tonic GABAergic inhibition of downstream neurons, resulting in enhanced neurotransmission of at least ACh and glutamate. As yet, there are no direct data linking the effects of 5-HT 6 receptors on GABA and the consequent release of DA and NE. A single study has suggested that the induction of dopamine release by 5-HT 6 receptor antagonists in the striatum may be through the modulation of ACh, 16 but again the absence of 5-HT 6 receptors on cholinergic neurons precludes them from being the initial target cells. There does not, as yet, appear to be any obvious downside to this unique neurochemical profile, in that 5-HT 6 receptor antagonists have been generally well tolerated in all of the human and preclinical studies reported to date. The ability of 5-HT 6 receptor antagonists to inhibit GABAergic function must be subtle: it is sufficient to produce cognitive enhancement, but does not reach levels that can lead to unwanted stimulant effects such as anxiety or enhanced seizure liability. Indeed, 5-HT 6 receptor antagonists are anxiolytic, and in some cases anticonvulsant.
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ADDITIONAL MECHANISMS OF ACTION
In addition to the regulation of neurotransmission, other mechanisms may contribute to the therapeutic potential of 5-HT 6 receptor antagonists in AD, including the induction of structural plasticity and regulation of Fyn kinase.
Structural plasticity refers to the physical flexibility of synapses, which enables the neuronal networks to adapt to and to process the constant flow of information in the brain. Increased structural plasticity is associated with improved learning and memory functions. A key mediator of interneuronal contacts is neural cell adhesion molecule (NCAM), which is expressed on the cell surface of perisynaptic neuronal processes. 62, 63 Although it is necessary for the induction of long-term potentiation and some forms of cognition, 64 -66 the plastic nature is achieved by the post-translational polysialylation of NCAM through the attachment of large homopolymers of ␣2,8 polysialic acid (PSA) to form PSA-NCAM. PSA provides antiadhesive properties that reduce the binding affinity between NCAM on neuronal processes, 67,68 thus promoting structural plasticity. Enzymatic removal of hippocampal PSA eliminates the induction and maintenance of hippocampal long-term potentiation, 69, 70 impairs spatial learning, 70, 71 and synaptogenesis on NCAM-expressing neurons. 72 The in vivo deletion of polysialyltransferase-1, an enzyme that attaches PSA to NCAM, can also lead to impairment of learning and memory. 73 In both rat and human hippocampus, PSA-NCAM is predominantly expressed in the subgranular zone of the dentate gyrus and along the mossy fibers. 74 -76 This anatomical localization is consistent with the identification of the subgranular zone as a neural stem cell niche where new neurons are produced throughout life and extend their dendrites to form the mossy fibers that extend to the CA3 region. Young neurons express high levels of PSA-NCAM, have greater degrees of structural plasticity, exhibit enhanced long-term potentiation, and appear to be preferentially inserted into neural circuits of memory. [77] [78] [79] [80] These findings led to the connotation that the upregulation of PSA-NCAM in the hippocampus is positively correlated with cognitive function. This is exemplified by several studies in different rat models of learning and memory, such as spatial learning in the Morris water maze and fear-conditioning. 71, 81, 82 The 5-HT 6 receptor antagonists SB-271046, 83, 84 SB-399885, 84 and SB-742457 5 have all been shown to augment the expression levels of PSA-NCAM in the dentate gyrus of the rat. The effect of the compounds on behaviorally naïve animals has been observed even after chronic dosing for 40 days, indicating the lack of desensitization of this induction effect. Furthermore, the acute or chronic predosing of SB-271046 to rats undergoing training in a Morris water maze paradigm significantly increased the level of PSA-NCAM above that induced by training alone in the water maze. 83 This is in line with the ability of SB-271046, SB-399885, and SB-742457 to significantly improve learning and memory in the aged rat Morris water maze task. 5, 19, 84 These data demonstrate the ability of 5-HT 6 receptor antagonists to induce the expression of PSA-NCAM, a vital mediator of neural plasticity and cognition, in a brain region that is critical for learning and memory. Notably, a PSA-NCAM mimotope (a cyclic 12-amino acid peptide that can conformationally mimic antigenic specificity) designated PR 21C is currently undergoing preclinical development by Pharmaxon (Marseilles, France) aiming for target indications of mild cognitive impairment and Alzheimer's disease (http://www.pharmaxon.com/#42). Figure 2 provides a hypothetical model linking the effects of 5-HT 6 receptor antagonists on cognition, glutamate release and PSA-NCAM expression.
A single recent report on the physical and functional association of 5-HT 6 receptors with Fyn kinase has raised an intriguing, though speculative, new angle on 5-HT 6 receptor antagonism. Activation of 5-HT 6 receptors leads to phosphorylation of tyrosine 420 on Fyn, an activating phosphorylation, as well as Fyn-dependent activation of Erk1/2. 85 This novel finding could have farreaching implications in AD, because of the potentially deleterious effects of active Fyn in ␤-amyloid toxicity, 86 synaptic and cognitive impairments, 87 and phosphorylation of tau. 88 It can be hypothesized that the activation of Fyn by 5-HT 6 receptors would exacerbate these pathological consequences; in this way, antagonism of the 5-HT 6 receptor may be protective. On the other hand, active Fyn supports excitatory synaptic transmission by mediating the membrane recruitment of NMDA receptors in the postsynaptic density, 89 while mice deficient in Fyn exhibit defective long-term potentiation, impaired special memory, and increased fearfulness. 90, 91 Thus, the potential therapeutic relevance of the 5-HT 6 receptorFyn pathway remains to be clarified.
CONCLUSIONS
Alzheimer's disease is one of the most important medical, social, and economic problems confronting contemporary society. Although cholinesterase inhibitors and, introduced more recently, memantine (a reported modulator of glutamatergic function 92 ) represent an advance in the treatment of AD, they are by no means panaceas. For example, a review of the available data on the use of donepezil for dementia due to
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AD concluded that treatment effects are small and not always apparent in clinical practice. 93 Unwanted side effects (largely peripheral in nature) can also be problematic. Thus, there is still a clear need to develop novel approaches to the symptomatic relief of AD that differentiate from current treatment options either in improved efficacy and tolerability profiles, responder rates, or overall clinical benefit.
Because neurochemical losses or imbalances in AD are not restricted only to the cholinergic or glutamatergic systems, it is expected that, to deliver more effective therapies in the future, agents that modulate several neurotransmitter pathways will be required. Indeed, clinical data have already shown that patients with moderate to severe AD who received donepezil (the most widely used ChEI) coadministered with memantine had significantly greater cognitive improvement than did those given donepezil alone. 94 This finding is in keeping with the view that it is the balance of effect on pairs of neurotransmitters that will ultimately be important in determining therapeutic outcome. 4 At present, many compounds that alter the function of varied neurotransmitters are being developed with AD as a target indication. Of these, the 5-HT 6 receptor antagonists appear to hold much potential as new therapies, because in preclinical studies they are clearly able to modulate multiple neurotransmitter systems and by so doing enhance cognition and attenuate anxiety and depression-like behaviors. It is even more encouraging that this initial promise has now translated into the first demonstration of clinical efficacy of a 5-HT 6 receptor antagonist (SB-742457) in AD patients, and that cognitive
FIG. 2.
Regulation of PSA-NCAM expression in the dentate gyrus by 5-HT 6 receptor antagonists. Top: Induction of PSA-NCAM expression on granule neurons in the dentate gyrus of rats treated for 40 days with SB-271046. PSA-NCAM immunofluorescence is localized to the neuronal cell body in the subgranular/granular layers (*) and dendritic processes that extend into the molecular layer (M) of the dentate gyrus. PSA-NCAM immunofluorescence is also expressed on the mossy fiber (MF) axons in the hilus region (H), although to a lesser extent. After treatment with SB-271046, a striking increase in the number of neurons in the subgranular/granule layers expressing PSA-NCAM immunofluorescence was observed. Images prepared by A.G. Foley and courtesy of C.M. Regan, Department of Pharmacology, The Conway Institute, University College Dublin. Bottom: A hypothetical model for the induction of PSA-NCAM expression. 5-HT 6 receptor antagonists reduce the tonic activation of GABA release, 22 thus suppressing the inhibitory tone on glutamatergic neurons and resulting in elevated glutamate release in the hippocampus. Glutamate promotes the neuronal differentiation of neural progenitor cells, a process that entails the transitory formation of immature young neurons, which express elevated levels of PSA-NCAM. 75 The effect of glutamate on the neural progenitors appears to specifically affect only the differentiation process, without increasing their proliferation rate, 97 which is in accord with the lack of any effect by SB-271046 on the proliferation index in the dentate gyrus. 84 The increased level of PSA-NCAM contributes to improved cognition, and may form a positive feedback loop with cognitive activities, given that brain activity associated with learning can induce PSA-NCAM expression. 82, 98, 99 enhancement was attained at doses of SB-742457 that were generally well tolerated.
The outcome of continued studies in AD (and also potentially other disorders characterized by cognitive deficits, such as schizophrenia and Parkinson's disease) with SB-742457 and alternative 5-HT 6 receptor antagonists currently at earlier stages of development is therefore eagerly awaited. Only then will it be known whether 5-HT 6 receptor antagonists are truly more advantageous than existing therapies, or than the many other mechanistic classes of symptomatic approaches presently under clinical evaluation, but at the very least there is substantive reason to remain optimistic at this stage.
